PD-1/PD-L1 inhibitors

Phase 2Small molecule

PD-1/PD-L1 inhibitors is one of 99 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaActive, not recruiting

HepatitisActive, not recruiting

InfluenzaActive, not recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Active, not recruiting

HepatitisPreclinical

Active, not recruiting

InfluenzaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Fluzone

Sanofi

Preclinical

16 2

Crestor

AstraZeneca

Preclinical

1 3

Trexall

Alnylam Pharmaceuticals

Preclinical

1 4

PD-1/PD-L1 inhibitors

CChuangzhen Chen

Phase 2

1 5

Avigan

AAppili Therapeutics Inc.

Preclinical

6 6

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 7

COMIRNATY

Pfizer

Preclinical

1 8

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 9

Fluvirin

Novartis

Preclinical

3 10

Diphtheria-Tetanus-Acellular Pertussis Vaccine

CanSino Biologics Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Metastatic Solid Tumors

NCT06076135

Q4 2028

Phase 2Active, not recruiting

Esophageal Squamous Cell Carcinoma

NCT07339488

Clinical

Trials by Indication[1]

Hepatitis1 trial

The Prediction Biomarkers of Survival Outcome for Severe Immune-related Hepatitis

Completed·HHunan Province Tumor Hospital··NCT05326906·20 enrolled

Esophageal Squamous Cell Carcinoma1 trial

Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma

Active, not recruiting·CChuangzhen Chen·Phase 2·NCT07339488·43 enrolled

Immune Checkpoint Inhibitors1 trial

SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors

Recruiting·FFudan University·Phase 2·NCT04767009·59 enrolled

Metastatic Solid Tumors1 trial

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid Tumors

Active, not recruiting·CChuangzhen Chen·Phase 2·NCT06076135·16 enrolled

Influenza1 trial

Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

Unknown status·SShanghai Pulmonary Hospital, Shanghai, China··NCT04355806·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for PD-1/PD-L1 inhibitors. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PD-1/PD-L1 inhibitors compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PD-1/PD-L1 inhibitors. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chuangzhen Chen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CChuangzhen Chen

PD-1/PD-L1 inhibitors

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2028

Trials by Indication[1]

Hepatitis1 trial

Esophageal Squamous Cell Carcinoma1 trial

Immune Checkpoint Inhibitors1 trial

Metastatic Solid Tumors1 trial

Influenza1 trial

References

Drug Info

Quick Facts

Related News